CN Patent

CN112601516A — 治疗与s1p1受体相关的病况的方法

Assigned to Arena Pharmaceuticals Inc · Expires 2021-04-02 · 5y expired

What this patent protects

本文提供了治疗鞘氨醇1‑磷酸盐亚型1(S1P 1 )受体相关病症的方法，包含向有需要的个体开处和/或投与标准剂量的(R)‑2‑(7‑(4‑环戊基‑3‑(三氟甲基)苄氧基)‑1,2,3,4‑四氢环戊并[b]吲哚‑3‑基)乙酸(化合物1)或其药学上可接受的盐、水合物或溶剂合物。

USPTO Abstract

本文提供了治疗鞘氨醇1‑磷酸盐亚型1(S1P 1 )受体相关病症的方法，包含向有需要的个体开处和/或投与标准剂量的(R)‑2‑(7‑(4‑环戊基‑3‑(三氟甲基)苄氧基)‑1,2,3,4‑四氢环戊并[b]吲哚‑3‑基)乙酸(化合物1)或其药学上可接受的盐、水合物或溶剂合物。

Drugs covered by this patent

Patent Metadata

Patent number
CN112601516A
Jurisdiction
CN
Classification
—
Expires
2021-04-02
Drug substance claim
No
Drug product claim
No
Assignee
Arena Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.